BioEcho Life Sciences announces FDA listing of its EchoLUTION Viral RNA/DNA Kit for nucleic acid extraction

Rapid and accurate clinical diagnostic tests are essential for the detection of viral infections and proper medical care. The EchoLUTION Viral RNA/DNA Kit is specifically designed for the extraction of viral nucleic acids from a variety of samples: It is particularly useful for the detection of respiratory viruses, as well as enteropathogenic viruses contained in stool samples. The kit is IVDR-compliant, CE-marked, and FDA-listed, making it an ideal solution for diagnostic laboratory routines that require high-quality standards. With a more sustainable composition it delivers the same performance as the previously available EchoLUTION Viral RNA/DNA Swab Kit Plus. This predecessor kit has been extensively used in Europe for rapid PCR diagnostics during the SARS-CoV-2 pandemic, with more than 12 million tests performed.

“BioEcho is proud to provide a product that enables convenient extraction of viral RNA and DNA. We believe these products, which are FDA-listed in the US, will have a significant impact on improving efficiency for diagnostics laboratories and ultimately decreasing response times for patients”, underlines Lydia Willing, General Manager at BioEcho Life Sciences, Inc.

One of the key benefits of the EchoLUTION Viral RNA/DNA Kit is its technology, which is based on a tailored lysis followed by nucleic acid purification in a single centrifugation step. For respiratory viruses, no incubation is needed, for stool samples it is as short as 10 minutes. This means that the purified viral RNA or DNA from 96 samples is ready to use within 20–30 minutes depending on the sample type (swabs in medium, dry swabs, or stool samples). The kit is available in different formats (48-and 96-well plates) to adapt laboratory throughput to demands. The product is compatible with a variety of downstream applications such as qPCR.

Über die BioEcho Life Sciences GmbH

BioEcho Life Sciences is a specialized solution provider for the extraction and analysis of nucleic acids. We create disruptive technologies, products, and workflows that make downstream processing of nucleic acids easier and faster, significantly increase throughput, and deliver reliable results. Our patented EchoLUTION™ technology enables the fastest DNA and RNA extraction on the market – in just one single step. It reduces the associated plastic consumption by up to 70 %.
BioEcho was founded in 2016 by leading industry experts. The headquarter in Cologne, Germany, is certified according to ISO 9001 and ISO 13485.

BioEcho. The Nucleic Acid Experts.

Firmenkontakt und Herausgeber der Meldung:

BioEcho Life Sciences GmbH
Nattermannallee 1
50829 Köln
Telefon: +49 221 998897 0
http://www.bioecho.de/

Ansprechpartner:
Dr Laura Torres Benito
Scientific Communications Manager
Telefon: +49 221 998897-24
E-Mail: laura.torres.benito@bioecho.de
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel